Wednesday, November 11, 2020 12:32:01 PM
November 10, 2020 08:35 ET | Source: Equillium
LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equillium’s chief executive officer and Krishna Polu, M.D., Equillium’s chief medical officer, will present at two upcoming investor conferences in November 2020.
Event:
Date:
Time:
Location: Stifel 2020 Virtual Healthcare Conference
Wednesday, November 18, 2020
3:20 PM Eastern Time | 12:20 PM Pacific Time
Virtual Webcast
Event:
Date:
Time:
Location: Jefferies Virtual London Healthcare Conference
Thursday, November 19, 2020
6:10 PM GMT | 1:10 PM Eastern Time | 10:10 AM PM Pacific Time
Virtual Webcast
Live webcasts of both presentations will be available under the “Investors” section of the Company’s website at https://ir.equilliumbio.com/. Replays will be available for 30 days following each webcast.
About Itolizumab
Itolizumab is a clinical-stage, first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Itolizumab is currently being evaluated in multiple clinical trials in patients with severe diseases, including aGVHD, lupus nephritis, uncontrolled asthma, and will soon be evaluated in a clinical trial of patients with COVID-19. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited. Itolizumab is marketed in India under the trade name “ALZUMAb-L” for the treatment of chronic plaque psoriasis and has received emergency use approval in India to treat cytokine release syndrome in COVID-19 patients with moderate to severe acute respiratory distress syndrome.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including COVID-19, aGVHD, lupus nephritis and uncontrolled asthma.
For more information, visit www.equilliumbio.com.
Investor Contact
Christine Zedelmayer, Chief Operating Officer
+1-858-412-5302
ir@equilliumbio.com
Media Contact
Katherine Carlyle Smith
Senior Account Associate
Canale Communications
+1-805-907-2497
katherine.smith@canalecomm.com
"Then there was a woman, a lion of a woman."
Recent EQ News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/17/2024 10:14:15 PM
- Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit • Business Wire • 09/10/2024 12:00:00 PM
- Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 09/04/2024 12:00:00 PM
- Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference • Business Wire • 08/28/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:10:26 PM
- Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights • Business Wire • 08/08/2024 08:01:00 PM
- Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease • Business Wire • 08/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2024 08:01:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2024 06:08:53 PM
- Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance • Business Wire • 07/18/2024 05:57:00 PM
- Equillium to Participate in Upcoming Investor Conferences • Business Wire • 07/02/2024 12:00:00 PM
- Equillium to be included in the Russell Microcap® Index • Business Wire • 06/12/2024 12:00:00 PM
- Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 06/05/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 12:00:55 PM
- Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata • Business Wire • 06/04/2024 12:00:00 PM
- Equillium to Present at the Jefferies Global Healthcare Conference • Business Wire • 05/29/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 09:56:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 09:00:15 PM
- Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease • Business Wire • 05/14/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:11:09 PM
- Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights • Business Wire • 05/09/2024 08:01:00 PM
- Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists • Business Wire • 05/07/2024 12:00:00 PM
- Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/03/2024 12:00:00 PM
- Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis • Business Wire • 04/01/2024 12:00:00 PM
- Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights • Business Wire • 03/25/2024 08:01:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM